+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease



How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease



Expert Review of Clinical Pharmacology 8(2): 201-210



We have provided a critical assessment of research on the reduction of cholesterol levels by statin treatment to reduce cardiovascular disease. Our opinion is that although statins are effective at reducing cholesterol levels, they have failed to substantially improve cardiovascular outcomes. We have described the deceptive approach statin advocates have deployed to create the appearance that cholesterol reduction results in an impressive reduction in cardiovascular disease outcomes through their use of a statistical tool called relative risk reduction (RRR), a method which amplifies the trivial beneficial effects of statins. We have also described how the directors of the clinical trials have succeeded in minimizing the significance of the numerous adverse effects of statin treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058012950

Download citation: RISBibTeXText

PMID: 25672965

DOI: 10.1586/17512433.2015.1012494


Related references

Comparing two cost-effectiveness studies of statins for the primary prevention of cardiovascular disease: Are statins cost-effective from a Korean health system perspective?. Clinical Therapeutics 31(12): 2916-2918, 2009

Use of statins in primary or secondary prevention of coronary heart disease is cost-effective in some but not all. Evidence-Based Cardiovascular Medicine 1(1): 26, 1997

Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. Cardiology Clinics 29(1): 87-103, 2011

Statins for secondary cardiovascular disease prevention for older primary care patients. Journal of the National Medical Association 101(7): 705-710, 2009

Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths. Texas Heart Institute Journal 40(3): 288-289, 2014

Polypills for the secondary prevention of cardiovascular disease: effective in improving adherence but are they safe?. Therapeutic Advances in Drug Safety 9(2): 157-162, 2018

Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?. Expert Opinion on PharmacoTherapy 9(9): 1437-1440, 2008

Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece. Clinicoeconomics and Outcomes Research 4: 135-143, 2012

Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease. Journal of Evaluation in Clinical Practice 23(2): 241-250, 2015

Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. American Heart Journal 151(2): 273-281, 2006

Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Yearbook of Endocrinology 2007: 118-119, 2007

Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 121(9): 1069-1077, 2010

Statins for secondary prevention of cardiovascular disease: the right dose. Pharmacology 87(1-2): 63-69, 2011

Unhealthy lifestyle, statins and the secondary prevention of cardiovascular disease. Internal Medicine Journal 37(6): 427-428, 2007

Are statins plus aspirin better than either agent alone for secondary prevention of cardiovascular disease?. American Journal of Geriatric PharmacoTherapy 2(2): 151-152, 2004